SIRT3 Deficiency Enhances Ferroptosis and Promotes Cardiac Fibrosis via p53 Acetylation
Cells · 2023
DOI: 10.3390/cells12101428 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Han Su und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA. Hauptthemen laut MEDLINE: Ferroptosis, Heart Failure, Sirtuin 3. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NHLBI NIH HHS, National Institute of General Medical Sciences and National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Cardiac fibrosis plays an essential role in the development of diastolic dysfunction and contributes to heart failure with preserved ejection fraction (HFpEF). Our previous studies suggested Sirtuin 3 (SIRT3) as a potential target for cardiac fibrosis and heart failure. In the present study, we explored the role of SIRT3 in cardiac ferroptosis and its contribution to cardiac fibrosis. Our data showed that knockout of SIRT3 resulted in a significant increase in ferroptosis, with increased levels of 4-hydroxynonenal (4-HNE) and downregulation of glutathione peroxidase 4 (GPX-4) in the mouse hearts. Overexpression of SIRT3 significantly blunted ferroptosis in response to erastin, a known ferroptosis inducer, in H9c2 myofibroblasts. Knockout of SIRT3 resulted in a significant increase in p53 acetylation. Inhibition of p53 acetylation by C646 significantly alleviated ferroptosis in H9c2 myofibroblasts. To further explore the involvement of p53 acetylation in SIRT3-mediated ferroptosis, we crossed acetylated p53 mutant (p534KR) mice, which cannot activate ferroptosis, with SIRT3KO mice. SIRT3KO/p534KR mice exhibited a significant reduction in ferroptosis and less cardiac fibrosis compared to SIRT3KO mice. Furthermore, cardiomyocyte-specific knockout of SIRT3 (SIRT3-cKO) in mice resulted in a significant increase in ferroptosis and cardiac fibrosis. Treatment of SIRT3-cKO mice with the ferroptosis inhibitor ferrostatin-1 (Fer-1) led to a significant reduction in ferroptosis and cardiac fibrosis. We concluded that SIRT3-mediated cardiac fibrosis was partly through a mechanism involving p53 acetylation-induced ferroptosis in myofibroblasts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA.
- Institute for Cancer Genetics, Columbia University, 1130 Nicholas Avenue, New York, NY 10032, USA.
ORCID-Profile: Aubrey C Cantrell, Jian-Xiong Chen
Förderung
- NIGMS NIH HHS
- NHLBI NIH HHS
- National Institute of General Medical Sciences and National Heart, Lung, and Blood Institute
- National Institute of General Medical Sciences of the National Institutes of Health
- National Heart, Lung, and Blood Institute
- University of Mississippi Medical Center Intramural Research Support Program
Zitieren
APA
Su, H., Cantrell, A. C., Chen, J. X., Gu, W., & Zeng, H. (2023). SIRT3 Deficiency Enhances Ferroptosis and Promotes Cardiac Fibrosis via p53 Acetylation. Cells. https://doi.org/10.3390/cells12101428
Vancouver
Su H, Cantrell AC, Chen JX, Gu W, Zeng H. SIRT3 Deficiency Enhances Ferroptosis and Promotes Cardiac Fibrosis via p53 Acetylation. Cells. 2023. doi:10.3390/cells12101428
BibTeX
@article{Su2023,
author = {Su, Han and Cantrell, Aubrey C and Chen, Jian-Xiong and Gu, Wei and Zeng, Heng},
title = {SIRT3 Deficiency Enhances Ferroptosis and Promotes Cardiac Fibrosis via p53 Acetylation},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12101428}
}
EUVIMED